Electra Therapeutics, Inc. (NASDAQ:ETRA) Stock Has Average Target Price of $34.00 According to Brokerages

Shares of Electra Therapeutics, Inc. (NASDAQ:ETRA) have earned a consensus recommendation of “Buy” from the five analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $34.00.

A number of analysts have recently weighed in on ETRA shares. Cantor Fitzgerald assumed coverage on Electra Therapeutics in a research note on Tuesday. They issued an “overweight” rating for the company. Evercore started coverage on shares of Electra Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $36.00 target price for the company. Jefferies Financial Group assumed coverage on shares of Electra Therapeutics in a research report on Tuesday. They set a “buy” rating and a $32.00 target price on the stock. Zacks Research upgraded shares of Electra Therapeutics to a “hold” rating in a research report on Wednesday. Finally, TD Cowen started coverage on shares of Electra Therapeutics in a research note on Tuesday. They set a “buy” rating on the stock.

Electra Therapeutics Trading Down 2.1%

Shares of NASDAQ:ETRA opened at $8.75 on Friday. Electra Therapeutics has a 52 week low of $8.50 and a 52 week high of $15.50.

Insider Activity at Electra Therapeutics

In related news, Director Orbimed Advisors Llc purchased 1,333,333 shares of the business’s stock in a transaction dated Monday, September 21st. The shares were bought at an average price of $15.00 per share, with a total value of $19,999,995.00. Following the purchase, the director directly owned 5,126,891 shares in the company, valued at $76,903,365. This trade represents a 35.15% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Carl Gordon bought 1,333,333 shares of Electra Therapeutics stock in a transaction on Monday, September 21st. The shares were bought at an average price of $15.00 per share, for a total transaction of $19,999,995.00. Following the acquisition, the director owned 5,126,891 shares of the company’s stock, valued at approximately $76,903,365. The trade was a 35.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

About Electra Therapeutics

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company’s research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body’s ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.